Socio-Demographic and Clinical Profile of Drug Resistant Tuberculosis Patients in a Tertiary Care Centre of Kolkata
Keywords:Tuberculosis, Drug Resistance, Extensively Drug-Resistant Tuberculosis, X-rays, India
Background: Drug resistant tuberculosis is a major public health threat that hinders progress in tuberculosis control worldwide. In 2019, India contributed highest cases of TB (27%) Worldwide. In 2019, 3.3% of new TB cases and 18% of previously treated cases had MDR/RRTB worldwide and India (27%) had the largest share of the global burden. This study was done to find out the sociodemographic and clinical profile of drug resistant TB patients. Methodology: It is an observational descriptive study with cross-sectional design, conducted at the drug resistant tuberculosis centre of R. G. Kar Medical College of Kolkata, West Bengal. Study Population consisted of the patients who were registered for the DR-TB regimen. Study duration was July 2016 –March 2017. Pre-tested, semi-structured schedule was designed to capture their sociodemographic profile, treatment history, clinical findings and available medical records. Data were compiled in MS Excel and analyzed in IBM SPSS 23.0. Results: Out of 159 cases, 27% patients were between 21-30 years. Males were predominant (68.6%). Most patients (56.6%) were underweight (BMI<18.5kg/m2). HIV seropositivity was found in 4 (2.5%) cases. Among all cases, 81.1% had history of taking ATD and 34.4% was cured in previous episode of treatment. The commonest associated comorbidity was DM (15.7%). Rifampicin resistance (93.1%) was most common followed by Isoniazid (8.2%). Pallor was found among 94.3% patients. Most patients had bilateral (62.3%) and moderately extensive (57.2%) lesions in chest x-ray. Conclusion: DR-TB control should focus adequately on younger age group as numbers of resistance is increasing among them. Relapse in previously cured cases was found to be major contributor of DR-TB suspect cases. Though, Rifampicin resistance was so common but prevalence of resistance to 2nd line drugs is still low. Focus should be given on early detection of drug resistance in all TB cases and improvement of nutritional status of the TB patient.
TB20_Exec_Sum_20201022.pdf [Internet]. [cited 2021Dec25]. Available from: https://www.who.int/tb/publications/global_report/TB20_Exec_Sum_20201022.pdf?ua=1
_eng.pdf [Internet]. [cited 2021Dec25]. Available from: https://apps.who.int/iris/bitstream/handle/10665/79199/9789241505345_eng.pdf;jsessionid=31D94979489BF388A4AE2FA424BBFDB0?sequence=1
TB profile [Internet]. [cited 2021Dec25]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&iso2=%22IN%22
Sinha P, Srivastava GN, Gupta A, Anupurba S. Association of risk factors and drug resistance pattern in tuberculosis patients in North India. J Glob Infect Dis. 2017 ;9(4):139.
Mukherjee P, Karmakar PR, Basu R Lahiri SK. Sociodemographic and clinical profile of multi drug resistant tuberculosis patients: a study at drug resistant tuberculosis centers of Kolkata. IOSR Journal of Dental and Medical Sciences. 2015;14(8):52-8.
Udwadia Z, Moharil G. Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. Lung India. 2014;31(4):336.
Sharma SK, George N, Kadhiravan T, Saha PK, Mishra HK, Hanif M. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Indian J Med Res. 2009;130(4):392–5.
Gupta S, Bandyopadhyay D, Gupta S, Sadhukhan S, Banerjees S. A sociodemographic study of multidrug resistant tuberculosis cases from DOTS clinics of Kolkata. J Indian Med Assoc. 2012 Oct 1;110:723–5.
Sethi S, Mewara A, Dhatwalia SK, Singh H, Yadav R, Singh K, et al. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India. BMC Infect Dis. 2013;13(1):137.
Azhar GS. DOTS for TB relapse in India: A systematic review. Lung India. 2012 ;29(2):147.
Mondal R, Jain A. Extensively Drug-Resistant Mycobacterium tuberculosis, India. Emerg Infect Dis. 2007;13(9):1429–31.
Maurya AK, Kant S, Nag VL, Kushwaha R a. S, Dhole TN. Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India. Journal of Postgraduate Medicine. 2012;58(3):185.
Hanif M, Malik S, Dhingra VK. Acquired drug resistance pattern in tuberculosis cases at the State Tuberculosis Centre, Delhi, India. Int J Tuberc Lung Dis. 2009; 13(1):74–78
Jain A, Dixit P. Multidrug resistant to extensively drug resistant tuberculosis: What is next? J Biosci. 2008;33(4):605–16.
Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, et al. Multidrug-Resistant and Extensively Drug Resistant Tuberculosis in Kashmir, India. J Infect Dev Ctries. 2009 ;4(01):019–23.
Dholakia YN, Shah DP. Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program. Lung India. 2013 ;30(4):316.
How to Cite
Copyright (c) 2021 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.